B. Combe
University of British Columbia
3 Papers
B. Combe is an academic researcher from University of British Columbia. The author has contributed to research in topics: Clinical trial & Evidence-based medicine. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs: A one‐year randomized, placebo‐controlled study
TL;DR: Abatacept in combination with synthetic DMARDs was well tolerated and improved physical function and physician- and patient-reported disease outcomes, however, abatACEpt in conjunction with biologic background therapies was associated with an increase in the rate of serious adverse events.
415
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
Daniel Aletaha,Robert Landewé,Thomas Karonitsch,Joan M. Bathon,Maarten Boers,Claire Bombardier,Stefano Bombardieri,Hyon K. Choi,B. Combe,Maxime Dougados,Paul Emery,Juan J. Gomez-Reino,E.C. Keystone,Guillaume Koch,Tore K Kvien,Emilio Martín-Mola,Marco Matucci-Cerinic,Kaleb Michaud,James R. O'Dell,Harold E. Paulus,Theodore Pincus,Pamela Richards,Lee S. Simon,Jeffrey Siegel,Josef S Smolen,Josef S Smolen,T. Sokka,Vibeke Strand,Peter Tugwell,D. van der Heijde,P.L.C.M. van Riel,Steven C. Vlad,R. van Vollenhoven,M. M. Ward,Michael E. Weinblatt,George A. Wells,Barbara White,Frederick Wolfe,Bin Zhang,Angela Zink,David T. Felson +40 more
TL;DR: Adherence to these recommendations will provide the readership of clinical trials with more details of important outcomes, while the higher level of homogeneity may facilitate the comparison of outcomes across different trials and pooling of trial results, such as in meta-analyses.
197
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.
Daniel Aletaha,Robert Landewé,Thomas Karonitsch,Joan M. Bathon,Maarten Boers,Claire Bombardier,Stefano Bombardieri,Hyon K. Choi,B. Combe,Maxime Dougados,Paul Emery,Juan J. Gomez-Reino,E.C. Keystone,Guillaume Koch,Tore K Kvien,Emilio Martín-Mola,Marco Matucci-Cerinic,Kaleb Michaud,James R. O'Dell,Harold E. Paulus,Theodore Pincus,Pamela Richards,Lee S. Simon,Jeffrey Siegel,Josef S Smolen,T. Sokka,Vibeke Strand,Peter Tugwell,D. van der Heijde,P.L.C.M. van Riel,Steven C. Vlad,R. van Vollenhoven,M. M. Ward,Michael E. Weinblatt,George A. Wells,Barbara White,Frederick Wolfe,Bin Zhang,Angela Zink,David T. Felson +39 more
TL;DR: Adherence to these recommendations will provide the readership of clinical trials with more details of important outcomes, while the higher level of homogeneity may facilitate the comparison of outcomes across different trials and pooling of trial results, such as in meta-analyses.